|
Anemia, Macrocytic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Neutrophil depletion limited blood loss in these mice, whereas exogenous administration of G-CSF in colitic wild-type mice caused macrocytic anemia.
|
31448510 |
2020 |
|
Sepsis-Associated Encephalopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies on the roles of CCL11, CXCL10, and G-CSF may be especially important in terms of potential prevention of SAE between 4 and 24 h after the onset of sepsis.
|
31628962 |
2020 |
|
Diabetic Cardiomyopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy.
|
31237127 |
2020 |
|
Periodontal inflammation
|
0.010 |
Biomarker
|
disease |
BEFREE |
G-CSF neutralization in periodontal inflammation could alleviate neutrophil infiltration and periodontal tissue destruction in experimental periodontitis.
|
31765840 |
2020 |
|
Late onset neutropenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Late-onset neutropenia (LON) requiring granulocyte colony-stimulating factor occurred more frequently in the ABOi group than in the ABOc group (4 vs. 0 patients) (P < 0.001).
|
31673829 |
2020 |
|
Abdominal Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conjunction with other therapies (salicylates, mesalamine sulfasalazine and prednisone), G-CSF ameliorates inflammatory bowel symptoms, but doses must be limited because it increases spleen size associated with abdominal pain.
|
30451720 |
2019 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
|
31566813 |
2019 |
|
anaphylaxis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
On administration of G-CSF (10 µg/kg) he developed features of anaphylaxis.
|
31203715 |
2019 |
|
Bacteremia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The most common grades 3 to 4 adverse events of etoposide + G-CSF ± plerixafor were febrile neutropenia (69.35%), mucositis (51.62%), and bacteremia (20.97%).No fatal outcomes were observed.
|
30871977 |
2019 |
|
Bronchopulmonary Dysplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Below median G-CSF combined with elevated %CD90+ predicted BPD (positive predictive value = 100%).
|
31799226 |
2019 |
|
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The control and treatment groups after MCAO received vehicle or G-CSF (G-CSF 50 μg/kg) 6, 24, and 48 h after brain ischemia.
|
31005633 |
2019 |
|
Dehydration
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Further, CsF3'H showed comparatively higher expression in floral tissues particularly stigma and its expression was significantly enhanced in response to UV-B, dehydration and salinity stress indicative of its role in stress.
|
31054842 |
2019 |
|
Encephalitis, St. Louis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In serum, G-CSF levels tended to be higher in jSLE patients (adjusted p-value = 0.06).
|
30563424 |
2019 |
|
Hyperalgesia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The effect of rutin and its mechanisms of action were evaluated in a model of hyperalgesia induced by G-CSF in mice.
|
30945072 |
2019 |
|
Hairy Cell Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this retrospective study, we compared the incidence and duration of neutropenia and hospitalization in patients with HCL treated with cladribine followed by peg-filgrastim as primary prophylaxis versus daily filgrastim given "on demand" according to absolute neutrophil count (ANC).
|
31152919 |
2019 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.010 |
Biomarker
|
disease |
BEFREE |
To facilitate JCV elimination by accelerating immune reconstitution inflammatory syndrome (IRIS), all patients received subcutaneous filgrastim upon PML diagnosis and discontinuation of Nz; eight received plasma exchange (PLEX).
|
31139690 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In serum, G-CSF levels tended to be higher in jSLE patients (adjusted p-value = 0.06).
|
30563424 |
2019 |
|
Osteomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, we found that G-CSF level was significantly up-regulated in the serum from osteomyelitis patients infected by <i>S. aureus</i> Together, <i>S. aureus</i> infection might suppress the function of osteoblastic cells and induce progressive bone loss by up-regulating the level G-CSF, suggesting a therapeutic potential for G-CSF neutralization in combating bone loss in <i>S. aureus</i> osteomyelitis.
|
31175224 |
2019 |
|
Peripheral Neuropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Exposure-safety analyses supported the recommended brentuximab vedotin starting dose (1.2 mg/kg every 2 weeks), and effective management of peripheral neuropathy and neutropenia with dose modification/reduction and febrile neutropenia with granulocyte colony-stimulating factor primary prophylaxis.
|
31152605 |
2019 |
|
Pneumococcal Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Secondly, we demonstrated that G-CSF transcript lung levels were significantly increased during pneumococcal infection.
|
31776393 |
2019 |
|
Mycoplasma pneumonia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared with sequential treatment with azithromycin alone, pidotimod combined with azithromycin significantly reduced the expression levels of IL-10 and G-CSF in serum of children with mycoplasma pneumonia, improved the curative effect and reduced the occurrence of adverse reactions, which has high application value in clinic.
|
31410140 |
2019 |
|
Purpura, Thrombotic Thrombocytopenic
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, there has been no report describing G-CSF-producing carcinoma combined with TTP.
|
31479879 |
2019 |
|
Vasculitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
When clinicians administer PEGylated granulocyte-colony stimulating factor (G-CSF) to cancer patients, drug-associated vasculitis should be suspected.
|
31391329 |
2019 |
|
Ovarian Failure, Premature
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty adult female rats were randomly subdivided into five groups: normal control (control), cyclophosphamide (CTX) plus subsequent PBS (POI + PBS), CTX plus subsequent PRP (POI + PRP), CTX plus subsequent G-CSF-mobilized PBMCs (POI + PBMCs), and CTX plus subsequent G-CSF-mobilized PBMCs combined with PRP (POI + PBMCs + PRP).
|
31034039 |
2019 |
|
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the autopsy findings, a diagnosis of primary lung squamous cell carcinoma producing G-CSF associated with TTP was made.
|
31479879 |
2019 |